WaveMan
WaveMan · Company
CRSP · Crispr Therapeutics Ag
> Search tickers & screens ⌘K
LIVE
← All companies

CRSP CRISPR Therapeutics (CRSP) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001674416
Quote by TradingView
Form 144 · 4
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
242
13F, latest reported quarter
Conversions, 180 days
8
Codes C/M, not in net · $1.0M priced

What the filings say about CRSP

Insiders, 180 days
-$5.1M net sold
5 sellers · 38% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$2.2M
4 notices

CRISPR Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, CRISPR Therapeutics AG insiders sold a net $5.1M of stock across 129 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Kulkarni Samarth
Chief Executive Officer
SELL
2026-10-20 SECtraded 2026-10-19
47,837
$2.4M
-3.0%
Context
  • 75 earlier Form 4 trades (code P or S) here by this insider (75 sales), the last on Oct 14, 2026.
  • The trade is 15.3% of the 311,899 shares held after it.
  • 2 other insiders sold within 30 days.
  • 242 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Kulkarni Samarth sold about $2.4M of CRSP on Oct 19, 2026; 2 other insiders sold within 30 days and 242 funds added in the latest 13F quarter.
KASINGER JAMES R.
General Counsel and Secretary
SELL
2026-10-15 SECtraded 2026-10-14
1,040
$51.2K
-0.5%
Context
  • 16 earlier Form 4 trades (code P or S) here by this insider (16 sales), the last on Oct 6, 2026.
  • The trade is 1.1% of the 95,857 shares held after it.
  • 3 other insiders sold within 30 days.
  • 242 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: General Counsel and Secretary KASINGER JAMES R. sold about $51.2K of CRSP on Oct 14, 2026; 3 other insiders sold within 30 days and 242 funds added in the latest 13F quarter.
Kulkarni Samarth
Chief Executive Officer
SELL
2026-10-15 SECtraded 2026-10-14
4,098
$201.9K
-0.5%
Context
  • 74 earlier Form 4 trades (code P or S) here by this insider (74 sales), the last on Mar 23, 2026.
  • The trade is 1.6% of the 259,736 shares held after it.
  • 3 other insiders sold within 30 days.
  • 242 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Kulkarni Samarth sold about $201.9K of CRSP on Oct 14, 2026; 3 other insiders sold within 30 days and 242 funds added in the latest 13F quarter.
George Simeon
Director
SELL
2026-10-16 SECtraded 2026-10-14
14,514
$720.4K
-2.1%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Jul 16, 2025.
  • The trade is 93.7% of the 15,486 shares held after it.
  • 3 other insiders sold within 30 days.
  • 242 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director George Simeon sold about $720.4K of CRSP under a 10b5-1 plan on Oct 14, 2026; 3 other insiders sold within 30 days and 242 funds added in the latest 13F quarter.
KASINGER JAMES R.
General Counsel and Secretary
SELL
2026-10-08 SECtraded 2026-10-06
1,990
$119.5K
-8.2%
Context
  • 15 earlier Form 4 trades (code P or S) here by this insider (15 sales), the last on Sep 22, 2026.
  • The trade is 2.1% of the 94,784 shares held after it.
  • 3 other insiders sold within 30 days.
  • 242 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: General Counsel and Secretary KASINGER JAMES R. sold about $119.5K of CRSP under a 10b5-1 plan on Oct 6, 2026; 3 other insiders sold within 30 days and 242 funds added in the latest 13F quarter.
129 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 124 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$5.1M over 180 days
-$4.9M over 90 days
below 80% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
242 funds bought in last quarter
more than 93% of Pharma & Biotech
Revenue
-90.6% year over year
below 89% of Pharma & Biotech
Margin
-16569.8% net margin
the lowest in Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
17.1% of the float short (float per yahoo 2026-10-27) · 10.2 days to cover · settled 2026-10-15
more than 89% of Pharma & Biotech
What changed in the last 30 days
Oct 20Chief Executive Officer Kulkarni Samarth sold $2.6M (2 trades, Oct 14 to Oct 19)
Oct 16Director George Simeon sold $720.4K under a 10b5-1 plan (Oct 14)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 14Director SIMEON GEORGE filed to sell $720.4K by Oct 14 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 8General Counsel and Secretary KASINGER JAMES R. sold $119.5K under a 10b5-1 plan (Oct 6)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 6Officer JAMES KASINGER filed to sell $119.5K by Oct 6 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch CRSP

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-27.1%12M
-34%-22%-11%+1%2025-102025-122026-022026-042026-062026-082026-10 2026-01-22 · Kulkarni Samarth sold $3.6M2026-10-19 · Kulkarni Samarth sold $2.4M2026-01-22 · Prasad Raju sold $2.1M2026-01-06 · Prasad Raju sold $1.1M2026-01-20 · Kulkarni Samarth sold $1.1M2026-09-17 · Behbahani Ali sold $780.9K2026-10-14 · George Simeon sold $720.4K2026-09-22 · KASINGER JAMES R. sold $626.5K2026-03-11 · Kulkarni Samarth sold $517.3K2026-03-16 · Kulkarni Samarth sold $499.4K2026-03-23 · Kulkarni Samarth sold $468.7K2026-01-20 · Kulkarni Samarth sold $446.3K2026-02-19 · Kulkarni Samarth sold $366.3K2026-01-06 · Prasad Raju sold $347.0K2025-12-22 · Prasad Raju sold $308.2K2026-01-06 · Prasad Raju sold $300.2K2026-03-16 · Prasad Raju sold $282.2K2026-05-29 · Patel Naimish sold $210.6K2026-10-14 · Kulkarni Samarth sold $201.9K2025-12-22 · Prasad Raju sold $194.4K2026-03-16 · Prasad Raju sold $194.1K2026-03-23 · Prasad Raju sold $173.5K2026-03-16 · KASINGER JAMES R. sold $166.5K2026-03-16 · Patel Naimish sold $152.0K2026-03-23 · KASINGER JAMES R. sold $148.9K2026-03-11 · KASINGER JAMES R. sold $147.8K2026-10-06 · KASINGER JAMES R. sold $119.5K2026-02-19 · KASINGER JAMES R. sold $111.0K2025-12-22 · Prasad Raju sold $56.9K2026-10-14 · KASINGER JAMES R. sold $51.2K2026-10-14 · SIMEON GEORGE filed to sell $720.4K2026-10-06 · JAMES KASINGER filed to sell $119.5K2026-09-22 · JAMES KASINGER filed to sell $626.5K2026-09-17 · ALI BEHBAHANI filed to sell $780.9K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns CRSP: institutional holders (13F)

13F holdings, latest reported quarter
ARK Investment Management LLC
9,460,939 sh
$516.0M
BlackRock, Inc.
8,348,977 sh
$455.4M
Orbis Allan Gray Ltd
5,449,161 sh
$297.2M
Capital World Investors
4,749,525 sh
$259.0M
STATE STREET CORP
4,321,666 sh
$235.7M

Congress trades in CRSP

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

CRSP planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
SIMEON GEORGE
Filed 2026-10-14
$720.4K
JAMES KASINGER
Filed 2026-10-06
$119.5K
JAMES KASINGER
Filed 2026-09-22
$626.5K
ALI BEHBAHANI
Filed 2026-09-17
$780.9K

CRSP mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Global X Genomics & Biotechnology ETF
$2.1M position · as of 2026-05-31
3.8%
AXS Green Alpha ETF
$1.6M position · as of 2026-06-30
2.8%
iShares Genomics Immunology and Healthcare ETF
$3.0M position · as of 2026-07-31
1.6%
ROBO Global Healthcare Technology and Innovation ETF
$1.1M position · as of 2026-07-31
1.5%
PROFUND VP BIOTECHNOLOGY
$485.7K position · as of 2026-06-30
1.0%
BIOTECHNOLOGY ULTRASECTOR PROFUND
$919.1K position · as of 2026-07-31
0.8%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
12 registered trials, 5 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
6
Phase 1
1 active
1
Not applicable
1 active
5
Multi-phase
3 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$7.7M
$22.0M
$3.6M
-66%
+20%
2024
$33.2M
$10.0M
$5.6M
-35%
+14%
2023
$12.3M
$24.8M
$2.6M
+3%
+15%
2022
$20.7M
$1.7M
$3.9M
-33%
+11%
2021
$17.0M
-$27.4M
$5.6M
+24%
+25%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $5.1M sold by insiders over 180 days, 242 funds added last quarter, $2.2M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

CRSP financials

Revenue growth
-90.6%
XBRL, annual
Net margin
-16569.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$13.4M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-3,369%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$371.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.34x
long-term debt only, 2026-06-30; equity 2026-06-30
Cash flow to debt
-0.63x
TTM operating cash flow over long-term debt only, 2026-06-30
Return on equity
-26.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-19.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-24.1%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$5.0B
market value at close 2026-10-26 on 2026-07-31 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
FCF yield
-7.8%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$3.5M$37.3M$371.2M$1.2M
Operating income-$664.6M-$466.6M-$222.5M-$673.2M
Net income-$581.6M-$366.3M-$153.6M-$650.2M
EPS (diluted)-6.47-4.34-1.94-8.36
Operating cash flow-$345.0M-$142.8M-$260.4M-$495.7M
Cash$347.6M$298.3M$389.5M$211.9M
Long-term debt$0n/an/an/a
SEC XBRL, fiscal years, as known on 2026-10-28

CRSP Stock Sonar score 6/7 axes

Find similar shapesCompare

CRSP ranks highest on institutional and government (93rd percentile) and profitability (69th), and lowest on insider conviction (11th), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
69
Inputs
  • Return on equity-26.1% · 69 pct, sector of 545
  • Return on assets-19.3% · 67 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-24.1% · 71 pct, sector of 576
Financial health
48
Inputs
  • Debt to equity0.34x · 38 pct, sector of 352
  • Cash flow to debt-0.63x · 58 pct, sector of 371
Growth
11
Inputs
  • Revenue growth, YoY-90.6% · 11 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
11
Inputs
  • Net Form 4 buying (codes P and S), 180d-$3.6M · 22 pct, sector of 429
  • Insider buyers, 180d0 · 0 pct, sector of 438
Institutional and government
93
Inputs
  • Funds adding, latest quarter242 · 93 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
41
Inputs
  • Short interest, % of float+17.1% · 20 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+8.3% · 62 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

CRSP filings, in plain words

Are CRISPR Therapeutics insiders buying or selling CRSP?

In the 180 days to 2026-10-28, CRISPR Therapeutics insiders were net sellers, a net $5.1M across purchases and sales reported on Form 4, by 5 sellers.

Are there planned insider sales of CRSP?

Yes. 4 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $2.2M of stock; the latest, by SIMEON GEORGE, was filed 2026-10-14.

Read the full summary

In the 180 days to 2026-10-28, CRISPR Therapeutics insiders were net sellers of CRSP, a net $5.1M across purchases and sales reported on Form 4 by 5 sellers. 38% of the 8 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 4 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $2.2M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies